Sierra Oncology, Inc. (SRRA)
Stock Price:
$12.42 USD
0.26 (2.14%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
129.11M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-108.74M |
| Shares Out |
10.40M |
| EPS (ttm) |
-15.27 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$12.42 |
| Previous Close |
$12.16 |
| Change ($) |
0.26 |
| Change (%) |
2.14% |
| Day's Open |
12.16 |
| Day's Range |
12.16 - 12.42 |
| Day's Volume |
6,073 |
| 52-Week Range |
8.55 - 22.00 |
More Stats
| Market Cap |
129.11M |
| Enterprise Value |
6.14M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
10.40M |
| Float |
4.84M |
| EPS (basic) |
-19.82 |
| EPS (diluted) |
-15.27 |
| FCF / Share |
-4.60 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
9,529 |
| Short Ratio |
0.68 |
| Short % of Float |
0.20% |
| Beta |
1.33 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.08 |
| Revenue |
n/a |
| Operating Income |
-70.87M |
| Net Income |
-108.74M |
| Free Cash Flow |
-47.82M |
| Net Cash |
122.97M |
| Net Cash / Share |
11.83 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-40.27% |
| ROE |
-116.22% |
| ROIC |
629.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$25.75*
(107.33% upside)
Low
17.0
Current: $12.42
High
33.0
Target: 25.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -66.99 | -55.42 | -42.62 | -48.08 | -35.83 | -22.58 | -4.01 |
| Net Income | -88.28 | -53.34 | -42.02 | -47.87 | -53.26 | -23.87 | -6.83 |
| Shares Outstanding | 2.91 | 1.77 | 1.25 | 0.76 | 0.36 | 0.03 | 0.02 |
| Earnings Per Share | -30.30 | -30.16 | -33.68 | -63.20 | -1,258.80 | -2,763.20 | -767.20 |
| Operating Cash Flow | -51.18 | -45.12 | -36.16 | -41.16 | -28.27 | -21.79 | -3.57 |
| Capital Expenditures | -0.04 | -0.12 | -0.09 | -0.17 | -0.41 | -0.19 | - |
| Free Cash Flow | -51.22 | -45.23 | -36.26 | -41.33 | -28.68 | -21.97 | -3.57 |
| Cash & Equivalents | 148 | 106 | 100 | 109 | 150 | 39.16 | 2.43 |
| Total Debt | 0.37 | 4.89 | - | - | - | - | 0.41 |
| Net Cash / Debt | 147 | 101 | 100 | 109 | 150 | 39.16 | 2.02 |
| Assets | 151 | 109 | 102 | 111 | 153 | 40.57 | 2.46 |
| Liabilities | 64.98 | 14.99 | 7.47 | 7.73 | 7.40 | 4.01 | 1.76 |
| Book Value | 86.35 | 94.48 | 94.73 | 103 | 145 | -108 | -34.69 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Sierra Oncology, Inc. |
| Country |
Canada |
| Employees |
71 |
| CEO |
Stephen George Dilly |
Stock Information
| Ticker Symbol |
SRRA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SRRA |
| IPO Date |
July 16, 2015 |
Description
Sierra Oncology researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor Checkpoint kinase 1 is being investigated in two Phase 1/2 clinical trials; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.